Antibody-based diagnostics are tests that utilize antibodies to detect specific molecules that are indicative of a particular disease or condition. These diagnostic tools leverage the high specificity of antibodies, and the ability to produce large quantities of them. For example, monoclonal antibodies (mAbs) or polyclonal antibody preparations can be developed to recognize unique antigenic determinants on specific pathogens associated with a disease.1
Various antibody-based diagnostic tests are now in use, including the enzyme-linked immunosorbent assay (ELISA), rapid diagnostic tests, western blotting, and immunohistochemistry. These methods are widely applied in infectious diseases, oncology, and even monitoring for autoimmune disorders.
In addition to detecting disease-associated molecules, antibody-based diagnostics may also be used to determine if someone has been previously exposed to a pathogen. For instance, antibody detection tests for HIV or COVID-19 antibodies can determine if an individual was previously infected, even if no symptoms are shown.2
A range of antibody-based diagnostic techniques is currently employed in clinical and research settings. Some of the most widely used include:
A staple in diagnostics, ELISA employs antibodies to detect and quantify antigens, such as proteins or pathogens, in biological samples. Subtypes such as sandwich ELISA and competitive ELISA are widely used, each offering unique advantages depending on the target analyte. ELISA is commonly used for diagnostic tests such as those for HIV, hepatitis, and pregnancy. The test is highly sensitive and can be performed relatively quickly.
RDTs use antibodies embedded in test strips to provide quick and portable diagnostic results. These tests are especially useful in point-of-care testing, such as diagnosing malaria or COVID-19 in a clinical environment where fast results are needed. Many are designed to detect neutralizing antibodies following infection or vaccination.
A more specialized technique used to detect specific proteins within a sample. After separating proteins by size through gel electrophoresis, antibodies are used to bind target proteins. This method is often used to confirm the presence of HIV after an initial positive result from an ELISA. It can also detect anti-drug antibodies in therapeutic monitoring.
IHC is used in pathology to detect the presence of specific antigens in tissues. This technique combines antibodies with chemical labels to visualize the distribution and localization of proteins in a tissue section. IHC is crucial in cancer diagnostics, helping to identify tumor markers and guide treatment decisions. It also provides insight into antibody isotypes and their tissue-specific activity.
Each of these tests leverages the unique properties of antibodies to detect target antigens with a high degree of accuracy and reliability, making them invaluable in the early detection and monitoring of diseases.
Related: Antibody Basics: Part 11 - Diagnostics - ELISA, Western blot, fluorescence
One of the critical advantages of antibody-based diagnostics is their ability to detect both active infections and prior exposure to pathogens. This feature is especially useful in situations where patients may not display overt symptoms but have been exposed to a pathogen. For instance:
HIV Testing: Antibody-based tests can detect HIV infection by identifying antibodies that the immune system produces in response to the virus. Even though HIV may remain dormant for years without symptoms, antibody tests can provide an early diagnosis, which is crucial for starting treatment before the disease progresses.
COVID-19 Serology Testing: Similar to HIV tests, COVID-19 serological tests detect the presence of antibodies to SARS-CoV-2, the virus responsible for COVID-19. This can be used to assess whether an individual has previously been infected, even if they were asymptomatic. Serology testing was particularly useful during the pandemic to track the spread of the virus and determine immunity levels in populations.
Influenza and Hepatitis Detection: Influenza and hepatitis viruses are additional examples of pathogens that can be monitored through antibody-based tests. For hepatitis B, detecting antibodies against specific viral proteins helps determine both current and past infections, guiding treatment protocols and prevention strategies.
Autoimmune Disorders: In autoimmune diseases, such as lupus, tests for antinuclear antibodies provide valuable insights into disease progression and treatment monitoring.
In each case, antibody-based diagnostics provide crucial information about a patient’s exposure history, immune response, and potential for transmission, guiding effective medical intervention and public health strategies.
Antibody-based diagnostics provide accurate results across many diseases, but they also have strengths and challenges that affect their reliability in clinical use.
High sensitivity and specificity: Antibodies are designed to bind only to their target antigens, which minimizing cross-reactions and enabling accurate antigen-antibody binding.
Scalable and adaptable across disease areas: From infectious diseases like HIV and COVID-19 to cancer diagnostics, antibody-based platforms can be applied in diverse healthcare and research settings. Their adaptability also supports drug discovery and large molecule development programs.
Ability to detect both current and past infections: These tests not only confirm active disease but also identify markers of prior exposure, giving clinicians valuable information about a patient’s immune history and potential immunity.
As antibody discovery and engineering techniques advance, the next generation of diagnostics is becoming even more precise, efficient, and adaptable to various medical and research needs. For example, the use of recombinant forms of antibodies generated through genetic engineering opens up new possibilities in diagnostic innovation. Recombinant antibodies can be produced more quickly and in larger quantities than traditional monoclonal antibodies, offering greater flexibility in their application. These developments also improve Fab-based antigen-antibody binding specificity, which is essential for accurate disease diagnosis.
Recent developments in biotechnology and engineering are expanding the capabilities of antibody-based testing. These innovations focus on increasing accuracy, reducing turnaround time, and broadening the range of detectable diseases.
Multiplex assay platforms: These systems measure several biomarkers in a single run, offering a complete diagnostic profile from one sample. They are especially valuable in cancer research, autoimmune disease monitoring, and infectious disease panels, where multiple signals must be evaluated together. Multiplexing reduces the need for repeat testing and improves laboratory efficiency.
AI-guided diagnostics: Artificial intelligence is being integrated into data analysis pipelines to interpret antibody test results with higher precision. By recognising subtle variations in binding patterns or fluorescence signals, AI reduces the risk of false results and supports clinical decision-making. It also accelerates assay development by predicting optimal antibody–antigen interactions.
Biosensors and miniaturized diagnostic devices: Advances in biosensor engineering and lab-on-a-chip technology allow complex antibody assays to be performed on portable devices. These tools deliver rapid, low-cost testing at the point of care, making them essential in outbreak response, rural healthcare, and resource-limited settings.
These innovations demonstrate how antibody-based diagnostics are moving beyond conventional laboratory applications, enabling faster, more reliable, and more accessible testing for a wide spectrum of diseases.
Siddiqui, M. Z. (2010). Monoclonal Antibodies as Diagnostics; an Appraisal. Indian Journal of Pharmaceutical Sciences, 72(1), 12-17. https://www.ijpsonline.com/archive.html
Deeks, J. J., Dinnes, J., Takwoingi, Y., Davenport, C., Spijker, R., Taylor-Phillips, S., Adriano, A., Beese, S., Dretzke, J., Harris, I. M., Price, M. J., Dittrich, S., Emperador, D., Hooft, L., Leeflang, M. M., & Accuracy Group, D. T. (2020). Antibody tests for identification of current and past infection with SARS‐CoV‐2. The Cochrane Database of Systematic Reviews, 2020(6). https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013652/full
For an antibody candidate, strong target binding is only part of the path toward……
Explore VHH-based biosensors for high-sensitivity detection using nanobodies in ……
Biointron’s Antibodies After Hours: BIO 2026 Reception was held at The Lion's Sh……
Explore how VHH antibodies stabilize protein conformations for crystallography, ……
You can also contact us on the Scientist and Science Exchange marketplaces.
